• Start
  • Cancer
  • Technology
    • Technology
    • Human Scaffolds
    • 3D Synthetic Scaffolds
  • Products & Services
  • Pipeline
  • News
  • Publications
  • Partners & Customers
  • About
Curing cancer by generating precision medicine Curing cancer by generating precision medicine Curing cancer by generating precision medicine Curing cancer by generating precision medicine
  • Start
  • Cancer
  • Technology
    • Technology
    • Human Scaffolds
    • 3D Synthetic Scaffolds
  • Products & Services
  • Pipeline
  • News
  • Publications
  • Partners & Customers
  • About

Archives

Monthly Archive for: "May, 2023"
Home » Archives for May 2023
Iscaffpharma presenting at SLAS Europe
 0
By Per Setterberg
In News
Posted May 14, 2023

Iscaffpharma presenting at SLAS Europe

Iscaffpharma and Elena Garre has been invited to present at SLAS Europe in Brussels. We are humbled that our technology gains such interest from the the research community and are confident that [...]

READ MORE
New chair of the board
 0
By Per Setterberg
In News
Posted May 12, 2023

New chair of the board

Iscaffpharma announces Sara Malcus as new chair of the board from May 2023. Sara brings experience from several start-ups and successful companies within biotech. We are proud to welcome Sara to [...]

READ MORE
Recent Posts
  • Business Developer
    Business Developer
    May 1, 2024
  • Iscaffpharma’s first patent issued by the United States Patent and Trademark Office
    Iscaffpharma’s first patent issued by the United States Patent and Trademark Office
    January 26, 2024
  • SLAS honors Per Setterberg as fellow member
    SLAS honors Per Setterberg as fellow member
    October 19, 2023
Recent Publications
  • 17. Ovarian tumor cells gain competitive advantage by actively reducing the cellular fitness of microenvironment cells
    17. Ovarian tumor cells gain competitive advantage by actively reducing the cellular fitness of microenvironment cells
    December 16, 2024
  • 16. Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development
    16. Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development
    April 26, 2024
  • 15. Proteomics of cell-free breast cancer scaffolds identify clinically relevant imprinted proteins and cancer-progressing properties
    15. Proteomics of cell-free breast cancer scaffolds identify clinically relevant imprinted proteins and cancer-progressing properties
    April 4, 2024
Contact us
  • Org nr: 559120-9753
  • Iscaff Pharma AB
    Erik Dahlbergsgatan 11A
    411 26 Gothenburg
    Sweden
  • contact@iscaffpharma.com
Copyright All Rights Reserved © 2023
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt